Breaking News
May 20, 2018 - Developmental psychotherapy aims at helping antisocial adolescents become responsible adults
May 20, 2018 - People with OCD process emotions differently than their unaffected siblings
May 20, 2018 - Interfering with enzyme’s movement may be new approach for developing of anti-cancer drugs
May 20, 2018 - Prestroke and poststroke oral anticoagulation therapy in AF patients
May 20, 2018 - Why drug users prefer heroin at home, but cocaine while out
May 20, 2018 - Gene therapy that reverses blindness in dogs could also help treat humans
May 20, 2018 - Opioid-Related Payments Linked to Increase in Opioid Rx
May 20, 2018 - Phone apps push people to take their pills
May 20, 2018 - Backbreaking Work May Shorten Men’s Lives
May 20, 2018 - Harsher drug laws won’t stop violence, argues former police chief
May 20, 2018 - Cognitive decline in dementia is not reduced by exercise
May 20, 2018 - Detecting breast cancer with non-invasive ‘disease screening pill’
May 20, 2018 - Simple treatment may minimize hearing loss triggered by loud noises
May 20, 2018 - Alignment of mother and offspring body clock could prevent diseases such as heart disease and obesity
May 20, 2018 - New commercial data warehouse for life sciences
May 20, 2018 - Practice Intervention Targeting IV Opioids May Cut Exposure
May 20, 2018 - New study provides insight into blood signatures of inflammation
May 20, 2018 - Scientists make breakthrough discovery about vitamin B12
May 20, 2018 - What Causes Cancer? Misconceptions Abound
May 20, 2018 - Proper burial of dead cells limits inflammation
May 20, 2018 - Study offers novel solution to suppress metastatic spread of deadly breast cancer
May 20, 2018 - Perspectives of patients and caregivers on care transitions
May 20, 2018 - Guidelines for weight gain in pregnancy should be changed for underweight and very obese women
May 20, 2018 - Researchers transplant retinal sheets derived from human embryonic stem cells in retinal degeneration mouse models
May 20, 2018 - U.S. military personnel at greater risk for skin cancer than general population
May 20, 2018 - Your immune system holds the line against repeat invaders, thanks to this molecule
May 20, 2018 - Between death and deportation
May 20, 2018 - Developing a High Throughput Mass Spectrometry Platform for Drug Discovery
May 19, 2018 - New project aims to increase awareness among hospital clinicians of non-beneficial treatment at end-of-life
May 19, 2018 - Automated bone scan index offers accurate, speedy prognostic information about prostate cancer
May 19, 2018 - Rutgers Cancer Institute nurses research various topics to enhance patient experience
May 19, 2018 - Computer models provide valuable insight to structure and function of Ebola, Zika viruses
May 19, 2018 - Study exposes key tactic used by deadly fungus
May 19, 2018 - Bacterial signals are crucial to development of pre-leukemic myeloproliferation, study shows
May 19, 2018 - Global experts identify key issues in supporting children with brain injuries transition back to school
May 19, 2018 - Social connections may protect black men who have sex with men from acquiring HIV
May 19, 2018 - Study IDs Factors Linked to Quality of Life With Dementia
May 19, 2018 - Potassium — Consumer
May 19, 2018 - HIV-1 viruses transmitted at birth are resistant to antibodies in mother’s blood
May 19, 2018 - Some water pitchers are much better at removing toxins, shows research
May 19, 2018 - Scientists discover how unusually long strands of RNA help colon cancer cells avoid death
May 19, 2018 - International study finds viable treatment option for people with mild asthma
May 19, 2018 - Mayo discovery could enable development of personalized ovarian, brain cancer treatments
May 19, 2018 - ‘Superbug’ Surfaces at Poultry Farm in China
May 19, 2018 - UCLA-designed program helps former HIV-positive inmates maintain health after release from jail
May 19, 2018 - New blood test could help avoid more than 40% of prostate biopsies, study finds
May 19, 2018 - Macrophages play key role in maintaining stem cell niche of mammary gland
May 19, 2018 - Ferritin Blood Test: MedlinePlus Lab Test Information
May 19, 2018 - Prolonged exposure to air pollution leads to genetic changes in rat brains, study finds
May 19, 2018 - Scientists identify new potential target to combat acute myeloid leukemia
May 19, 2018 - Ovarian cancer therapy may help treat patients with aggressive pancreatic cancer
May 19, 2018 - MediciNova Announces Opening of Investigational New Drug Application for MN-166 (ibudilast) in Glioblastoma
May 19, 2018 - Research shows that sexual activity and emotional closeness are unrelated to the rate of cognitive decline
May 19, 2018 - Nuffield Council on Bioethics outlines ethical issues arising from use of AI in healthcare
May 19, 2018 - Pancreatic cancer patients with BRCA1 or BRCA2 mutations fare better on platinum-based chemotherapy
May 19, 2018 - Tradeshow Talks with nal von minden Ltd
May 19, 2018 - Chemist begins new project to develop carbohydrate mimics to assist cancer therapies
May 19, 2018 - Healthy Lifestyle for Healthy Older Adults
May 19, 2018 - Epstein-Barr virus linked to seven serious diseases
May 19, 2018 - Biochemists isolate protein supercomplex from bacteria that generates voltage
May 19, 2018 - Mindfulness-based Stress Management Course for cancer survivors
May 19, 2018 - Simple screening tool can help identify people at increased risk for dementia
May 19, 2018 - Many gay and bisexual teenage boys use adult hookup apps to connect with friends, partners
May 19, 2018 - Maternal Exposure to Polluted Air Tied to Elevated Child BP
May 19, 2018 - Experimental drug extends survival in progeria
May 19, 2018 - FutureNeuro and GreenLight Medicines team up to develop cannabis-based treatments for epilepsies
May 19, 2018 - Brazilians with less education more likely to perceive as being in poor health
May 19, 2018 - Experts available to discuss subjects related to Ebola virus
May 19, 2018 - Opioid Makers’ Perks to Docs Tied to More Prescriptions
May 19, 2018 - AI detects patterns of gut microbes for cholera risk
May 19, 2018 - Researcher develops small molecules that inhibit derailment of gene expression in cancer
May 19, 2018 - Study brings fresh insights into biology of malaria parasite
May 19, 2018 - Microglia may play key role in slowing progression of prion diseases, research suggests
May 19, 2018 - Safety program successfully reduces SSIs in patients undergoing colorectal operations
May 19, 2018 - Clinical study supports usual medical care plus chiropractic care for low back pain
May 19, 2018 - Vermont legislators pass a drug importation law. So what?
May 19, 2018 - Trump proposes cutting planned parenthood funds. What does that mean?
May 19, 2018 - Cognitive training intervention reduces gait freezing in Parkinson’s patients, study shows
May 19, 2018 - Clinical trial begins enrollment to test safety of experimental MERS treatments
May 19, 2018 - Scientists disrupt two enzymes to shrink cancer cells
Loxo Oncology Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Larotrectinib for the Treatment of TRK Fusion Cancers

Loxo Oncology Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Larotrectinib for the Treatment of TRK Fusion Cancers

image_pdfDownload PDFimage_print

larotrectinib

Treatment for Solid Tumors

Loxo Oncology Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Larotrectinib for the Treatment of TRK Fusion Cancers

STAMFORD, Conn., Dec. 20, 2017 (GLOBE NEWSWIRE) — Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that the company has initiated submission of a rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for larotrectinib for the treatment of unresectable or metastatic solid tumors with NTRK-fusion proteins in adult and pediatric patients who require systemic therapy and who have either progressed following prior treatment or who have no acceptable alternative treatments. The company expects to complete the NDA submission in early 2018.

“The initiation of the NDA submission for larotrectinib is an important milestone for Loxo Oncology and a step towards the goal of treating cancer based on the genetic signature of a tumor rather than its location in the body,” said Josh Bilenker, M.D., chief executive officer of Loxo Oncology. “We are proud of the strong data underlying our application in both adult and pediatric patients and will continue to work expeditiously to complete the submission and bring this potential new medicine to patients with TRK fusion cancers.”

About Larotrectinib (LOXO-101)

Larotrectinib is a potent, oral and selective investigational new drug in clinical development for the treatment of patients with cancers that harbor abnormalities involving the tropomyosin receptor kinases (TRKs). Growing research suggests that the NTRK genes, which encode for TRKs, can become abnormally fused to other genes, resulting in growth signals that can lead to cancer in many sites of the body. In an analysis of 55 RECIST-evaluable TRK fusion adult and pediatric patients, larotrectinib demonstrated a 75 percent independently-reviewed confirmed overall response rate (ORR) and an 80 percent investigator-assessed confirmed ORR, across many different types of solid tumors. Larotrectinib has been granted Breakthrough Therapy Designation Rare Pediatric Disease Designation and Orphan Drug Designation by the U.S. FDA. For additional information about the larotrectinib clinical trials, please refer to www.clinicaltrials.gov. Interested patients and physicians can contact the Loxo Oncology Physician and Patient Clinical Trial Hotline at 1-855-NTRK-123 or visit www.loxooncologytrials.com.

In November 2017, Loxo Oncology and Bayer entered into an exclusive global collaboration for the development and commercialization of larotrectinib and LOXO-195, a next-generation TRK inhibitor. Loxo Oncology leads worldwide development and U.S. regulatory activities. Bayer leads ex-U.S. regulatory activities and worldwide commercial activities. In the U.S., Loxo Oncology and Bayer will co-promote the products.

About TRK Fusion Cancer

TRK fusions are chromosomal abnormalities that occur when one of the NTRK genes (NTRK1, NTRK2, NTRK3) becomes abnormally connected to another, unrelated gene (e.g. ETV6, LMNA, TPM3). This abnormality results in uncontrolled TRK signaling that can lead to cancer. TRK fusions occur rarely but broadly in various adult and pediatric solid tumors, including appendiceal cancer, breast cancer, cholangiocarcinoma, colorectal cancer, GIST, infantile fibrosarcoma, lung cancer, mammary analogue secretory carcinoma of the salivary gland, melanoma, pancreatic cancer, thyroid cancer, and various sarcomas. TRK fusions can be identified through various diagnostic tests, including targeted next-generation sequencing (NGS), immunohistochemistry (IHC), polymerase chain reaction (PCR), and fluorescent in situ hybridization (FISH). For more information, please visit www.TRKtesting.com.

About Loxo Oncology

Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company’s website at www.loxooncology.com.

Forward Looking Statements

This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including Loxo Oncology’s expectations regarding the timing and success of our clinical trials and timing, if any, of regulatory approval. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Further information on potential risk factors that could affect our business and its financial results are detailed in our most recent Quarterly Report on Form 10-Q, and other reports as filed from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Source: Loxo Oncology, Inc.

Posted: December 2017

larotrectinib FDA Approval History

Tagged with:

About author

Related Articles